PRTG Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	247 449
Średni wolumen	103 931
Kapitalizacja rynkowa	6.21M
EPS	$0 ( 2024-03-06 )
Następna data zysków	( $-0.220 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.00700 (2.23%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: 0.74 (moderate)

Signal:(46.523) Neutral

Portage Biotech Inc. Korelacja

10 Najbardziej pozytywne korelacje
GLBS	0.946
KOSS	0.944
MSEX	0.937
EBIX	0.936
TSLA	0.935
PLL	0.932
WALD	0.932
KRNY	0.931
VRM	0.931
MNSB	0.93

10 Najbardziej negatywne korelacje
FTIV	-0.938
KVSC	-0.934
NVCN	-0.923
TETC	-0.922
SPLK	-0.919
FLXS	-0.919
APXI	-0.916
VLAT	-0.914
ROVR	-0.914
ADAL	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Portage Biotech Inc. Korelacja - Waluta/Towar

-0.39
( neutral )

-0.37
( neutral )

0.00
( neutral )

-0.50
( weak negative )

Portage Biotech Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-1 000.00 (0.00 %)
EPS:	$-6.49

FY	2023
Przychody:	$0
Zysk brutto:	$-1 000.00 (0.00 %)
EPS:	$-6.49

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-1.470

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.350

Financial Reports:

No articles found.

Portage Biotech Inc.

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.